Affymetrix, Inc. provides life science tools and molecular diagnostic products that enable parallel analysis of biological systems at the gene, protein, and cell level primarily in the United States, Europe, Latin America, and Asia. The company operates in two segments, Affymetrix Core and eBioscience. The Affymetrix Core segment develops and markets GeneChip gene expression products and services, GeneTitan instrument systems, GeneAtlas instruments, QuantiGene singleplex and multiplex assays; Axiom genotyping solution, arrays with clinical research applications, and CytoScan cytogenetics arrays for genotyping and gene expression applications. This segment also offers reagents, such as ExoSAP-IT for a reagent for the clean-up of polymerase chain reaction, and HotStart-IT reagents; enzymes; purification kits; and biochemicals for life science researchers. The eBioscience segment is involved in the development, manufacturing, marketing, and distribution of research tools in the areas of flow cytometry, immunoassays, microscopic imaging, and other protein-based analyses. The company sells its products directly and through third party distributors to genomic research centers, academic institutions, government, and private laboratories, as well as pharmaceutical, diagnostic, and biotechnology companies. Affymetrix, Inc. was founded in 1991 and is headquartered in Santa Clara, California.
Key stats and ratios
|
| Net profit margin | -7.69% | -3.62% |
| Operating margin | -3.71% | -13.22% |
| EBITD margin | - | 3.39% |
| Return on average assets | -4.70% | -2.18% |
| Return on average equity | -9.44% | -3.88% |
| Employees | 1,100 | - |
|
|
|
Address
3420 Central Expressway
SANTA CLARA, CA 95051
United States
No comments:
Post a Comment